Genetic Technologies Ltd (GENE)

NASDAQ


	Symbol		Exchange		Currency
	GENE		NASDAQ		USD	Real-time
	GTG		Frankfurt		EUR	Delayed
	GTG		Sydney		AUD	Delayed

Currency in USD

0.765

0.000(0.00%)

Real-time Data16/10

Fair Value

Day's Range

0.765

0.790

52 wk Range

0.667

3.590

GENE Income Statement

Explore the detailed Genetic Technologies Ltd income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Genetic Technologies Ltd's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2015

30/06

2016

30/06

2017

30/06

2018

30/06

2019

30/06

2020

30/06

2021

30/06

2022

30/06

2023

30/06

2024

30/06

Total Revenues

0.84

1.33

9.22

10.35

9.67

Total Revenues Growth

+3,192.98%

+59.3%

+590.65%

+12.25%

-6.52%

Cost Of Revenues

0.1

0.17

3.01

4.34

3.76

Gross Profit

0.74

1.16

6.2

6.01

5.91

Gross Profit Growth

+393.61%

+58.1%

+432.93%

-3.1%

-1.67%

Gross Profit Margin %

87.89%

87.23%

67.31%

58.1%

61.12%

Other Operating Expenses, Total

6.67

8.59

13.75

16.43

16.51

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-1.36%	+28.63%	+60.13%	+19.49%	+0.47%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	0.87	1.17	0.71	1.28	0.75
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4.38	5.8	10.31	10.8	11.7
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1.17	1.24	2.15	3.67	3.52

Operating Income

-5.94

-7.42

-7.54

-10.42

-10.59

Operating Income Growth

+15.38%

-24.97%

-1.65%

-38.07%

-1.7%

EBIT Margin %

-708.77%

-556.03%

-81.84%

-100.66%

-109.52%

Net Interest Expenses

-0.05

0.05

0.02

0.19

0.07

Net Interest Expenses Growth

-959.88%

+192.94%

-54.31%

+806.07%

-64.39%

Interest Expense, Total

-0.07

-0.02

-0.02

-0.03

-0.05

Interest And Investment Income

0.02

0.06

0.04

0.22

0.12

Other Non Operating Expenses, Total

-0.6

0.01

0.36

0.16

-0.16

EBT, Excl. Unusual Items

-6.58

-7.37

-7.16

-10.06

-10.69

Gain (Loss) On Sale Of Assets

0.04

-

-

-

-

Other Unusual Items, Total

0.25

0.29

-

-

-

EBT, Incl. Unusual Items

-6.29

-7.08

-7.16

-11.91

-12.02

EBT, Incl. Unusual Items Growth

+2.04%

-12.44%

-1.21%

-66.26%

-0.91%

EBT, Incl. Unusual Items Margin

-751.29%

-530.26%

-77.71%

-115.09%

-124.24%

Income Tax Expense

-

-

-0.03

-0.16

-

Net Income to Company

-6.29

-7.08

-7.13

-11.75

-12.02

Minority Interest

-

-

-

-

-

Net Income

-6.29

-7.08

-7.13

-11.75

-12.02

Net Income Growth

+2.04%

-12.44%

-0.75%

-64.79%

-2.27%

Net Income Margin %

-751.29%

-530.26%

-77.36%

-113.56%

-124.24%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-6.29

-7.08

-7.13

-11.75

-12.02

Basic EPS - Continuing Operations

-0.15

-0.08

-0.08

-0.12

-0.09

Basic EPS - Continuing Operations Growth

+37.86%

+45.32%

+6.63%

-49.87%

+21.59%

Diluted EPS - Continuing Operations

-0.15

-0.08

-0.08

-0.12

-0.09

Diluted EPS - Continuing Operations Growth

+37.86%

+45.32%

+6.63%

-49.87%

+21.59%

Basic Weighted Average Shares Outstanding

41.55

85.44

92.2

101.38

132.22

Diluted Weighted Average Shares Outstanding

41.55

85.44

92.2

101.38

132.22

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-5.87

-7.16

-7.2

-10.04

-10.36

EBITDA Growth

+14.4%

-21.84%

-0.63%

-39.38%

-3.2%

EBITDA Margin %